Two causes of demyelinating neuropathy in one patient: CMT1A and POEMS syndrome

Canadian Journal of Neurological Sciences

Volumn 34, Issue 3, 2007, Pages 380-385

  Chahin, Nizar ^a   Zeldenrust, Steven R ^a   Amrami, Kimberly K ^a   Engelstad, JaNean K ^a   Dyck, P James B ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MELPHALAN;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEMYELINATING NEUROPATHY; ELECTROMYOGRAM; GENETIC PROCEDURES; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MALE; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSCLEROSIS; PARAPROTEINEMIA; PELVIS LYMPH NODE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RADIODIAGNOSIS;

EID: 34548419187     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100006892     Document Type: Article

References (31)

1. Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S. Maisonobe T, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain. 1997;120(Pt 5):813-23.
2. Dyck PJ, Dyck PJB, Chalk CH. The 10 P's: A mnemonic helpful in characterization and differential diagnosis of peripheral neuropathy. Neurology. 1992;42:14-8.
3. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496-506.
4. Dispenzieri A. POEMS Syndrome. Hematology (Am Soc Hematol Educ Program). 2005:360-7.
5. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8(6):590-6.
6. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66:219-32.
7. Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc. 1982;57:239-46.
8. Murakami T, Oomori H, Hara A, Uyama E, Mita S, Uchino M. Atypical phenotype of charcot-marie-tooth disease type 1A. Muscle Nerve. 1999;22(11):1593-6.
9. Malandrini A, Villanova M, Dotti MT, Federico A. Acute inflammatory neuropathy in Charcot-Marie-Tooth disease. Neurology. 1999;52(4):859-61.
10. Gabriel CM, Gregson NA, Wood NW, Hughes RA. Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a). J Neurol Neurosurg Psychiatry. 2002;72(2):230-5.
11. Vital A, Vital C, Lagueny A, Ferrer X, Ribiere-Bachelier C, Latour P, et al. Inflammatory demyelination in a patient with CMT1A. Muscle Nerve. 2003;28(3):373-6.
12. Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, et al. Coexistent hereditary and inflammatory neuropathy. Brain. 2004;127(Pt 1):193-202.
13. Carvalho AA, Vital A, Ferrer X, Latour P, Lagueny A, Brechenmacher C, et al. Charcot-Marie-Tooth disease type 1A: clinicopathological correlations in 24 patients. J Peripher Nerv Syst. 2005;10(1):85-92.
14. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 1954;251(10):396-400.
15. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822-30.
16. Dispenzieri A, Gertz MA. Treatment of Castleman's disease. Curr Treat Options Oncol. 2005;6(3):255-66.
17. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670-83.
18. Mallory A, Spink WW. Angiomatous lymphoid hamartoma in the retroperitoneum presenting with neurologic signs in the legs. Ann Intern Med. 1968;69(2):305-8.
19. Donaghy M, Hall P, Gawler J, Gregson NA, Leibowitz S, Jitpimolmard S, et al. Peripheral neuropathy associated with Castleman's disease. J Neurol Sci. 1989;89(2-3):253-67.
20. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347:702.
21. Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40(4):786-7.
22. Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21(11):1390-7.
23. Dyck PJ, Engelstad J, Dispenzieri A. Vascular endothelial growth factor and POEMS. Neurology. 2006;66(1):10-2.
24. Nishi J, Arimura K, Utsunomiya A, Yonezawa S, Kawakami K, Maeno N, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol. 1999;104(3):482-5.
25. Nishi J, Maruyama I. Increased expression of vascular endothelial growth factor (VEGF) in Castleman's disease: proposed pathomechanism of vascular proliferation in the affected lymph node. Leuk Lymphoma. 2000;38(3-4):387-94.
26. Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Del Bo R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911-20.
27. Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP. High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood. 2002;99(8):3057-9.
28. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104(10):3400-7.
29. Dispenzieri A, Gertz MA. Treatment options for POEMS syndrome. Expert Opin Pharmacother. 2005;6(6):945-53.
30. Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66(1):105-7.
31. Straume O, Bergheim J, Ernst P. Bevacizumab therapy for POEMS syndrome. Blood. 2006;107(12):4972-3; author reply 3-4.